title: Estramustine-binding protein (EMBP) in renal cell carcinoma immunohistochemistry, immunoscintigraphy and in vitro estramustine effects.
abstract: The present report shows that the human renal cell carcinoma (RCC) cell lines, A498 and CAKI-2, express the estramustine-binding protein (EMBP). The RCC cell lines investigated were highly sensitive for estramustine, with cell arrest in atypical metaphase. In vitro experiments using a fluorimetric cytotoxicity assay (FMCA) showed a pronounced cytotoxic effect mediated by estramustine. Immunohistochemical analysis of tumour specimens from patients with RCC showed positive staining for EMBP in 12/16 cases. Immunoscintigraphy was performed in an experimental system in nude mice, heterotransplanted with the CAKI-2 cell line. A radiolabelled monoclonal anti-EMBP antibody was used. The results show a specific uptake of the antibody in the RCC tumour, expressed as a percentage of the injected dose per gram tissue, which ranged from 4.03 to 6.9. The results obtained form the basis for clinical studies on the feasibility of utilizing estramustine in the management of RCC. Immunoscintigraphy using the monoclonal anti-EMBP antibody is of potential use for in vivo characterization of the malignancy and in the selection patients suitable for treatment with estramustine.
authors.affiliation: Department of Oncology, Akademiska sjukhuset, Uppsala University, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Edgren
authors.forename: J E
authors.initials: JE
authors.lastname: Westlin
authors.forename: H
authors.initials: H
authors.lastname: Letocha
authors.forename: H
authors.initials: H
authors.lastname: Nordgren
authors.forename: K M
authors.initials: KM
authors.lastname: Kälkner
authors.forename: S
authors.initials: S
authors.lastname: Nilsson
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D002352:Carrier Proteins / Q000032:analysis*; D004305:Dose-Response Relationship, Drug; D004961:Estramustine / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D005470:Fluorometry; D006801:Humans; D007150:Immunohistochemistry; D007457:Iodine Radioisotopes; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008677:Metaphase; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D029584:Prostatic Secretory Proteins; D016719:Radioimmunodetection; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002352:Carrier Proteins; D007457:Iodine Radioisotopes; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D004961:Estramustine